These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21515208)

  • 1. Stathmin immunoreactivity in phaeochromocytomas and paragangliomas: differential expression between benign and malignant neoplasms.
    Lin WC; Chen SC; Chuang YT; Kuo KL; Huang KH
    Asian J Surg; 2011 Jan; 34(1):15-22. PubMed ID: 21515208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
    Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
    Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative immunohistochemical study of phaeochromocytomas and paragangliomas.
    Fraga M; García-Caballero T; Antúnez J; Couce M; Beiras A; Forteza J
    Histol Histopathol; 1993 Jul; 8(3):429-36. PubMed ID: 8358154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
    Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
    J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
    Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
    J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stathmin as a marker for malignancy in pheochromocytomas.
    Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
    Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of S-100 protein in sustentacular cells of phaeochromocytomas and paragangliomas.
    Schroder HD; Johannsen L
    Histopathology; 1986 Oct; 10(10):1023-33. PubMed ID: 3536711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.
    Lee JP; Hung YP; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
    Histopathology; 2017 Oct; 71(4):503-510. PubMed ID: 28464318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management.
    Foo SH; Chan SP; Ananda V; Rajasingam V
    Singapore Med J; 2010 May; 51(5):e89-93. PubMed ID: 20593136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel Mutations and Expressions of
    Islam F; Pillai S; Gopalan V; Lam AK
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
    Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
    Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression profile of alternatively spliced neuronal c-src RNA distinguishes between human tumours of the sympatho-adrenal lineage.
    Ortoft E; Bjelfman C; Hedborg F; Grimelius L; Påhlman S
    Int J Cancer; 1995 Jan; 60(1):38-44. PubMed ID: 7529211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.
    Lee SE; Oh E; Lee B; Kim YJ; Oh DY; Jung K; Choi JS; Kim J; Kim SJ; Yang JW; An J; Oh YL; Choi YL
    Oncotarget; 2016 Apr; 7(17):24141-53. PubMed ID: 27007161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
    van der Harst E; Bruining HA; Jaap Bonjer H; van der Ham F; Dinjens WN; Lamberts SW; de Herder WW; Koper JW; Stijnen T; Proye C; Lecomte-Houcke M; Bosman FT; de Krijger RR
    J Pathol; 2000 Jun; 191(2):175-80. PubMed ID: 10861578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pheochromocytoma and sympathetic paragangliomas].
    Zollinger R; Hedinger C
    Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
    Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
    J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.
    de Krijger RR; van der Harst E; van der Ham F; Stijnen T; Dinjens WN; Koper JW; Bruining HA; Lamberts SW; Bosman FT
    J Pathol; 1999 May; 188(1):51-5. PubMed ID: 10398140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.